Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027627

Enrollment

Unknown

Registered

2019-11-22

Start date

2017-12-01

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

f PLA2R-associated primary membranous nephropathy

Interventions

experimental group:LEF combined with prednisone

control group:yclophosphamide (CTX) combined with prednisone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) age between 18 and 70 years; (2) nephrotic syndrome (24-h urinary protein >=3.5 g and serum albumin <=30 g/L); (3) confirmed PMN onset by renal biopsy in our hospital; (4) serum anti-PLA2R antibody positivity and/or renal tissue PLA2R antigen positivity; (5) no use of corticosteroids or immunosuppressive agents within the last 3 months.

Exclusion criteria

Exclusion criteria: (1) various secondary membranous nephropathies; (2) diabetes (fasting blood glucose >6.1 mmol/L); (3) malignant tumors; (4) severe infection; (5) abnormal liver function or allergies to the treatment; (6) pregnancy or lactation; (7) serious complications such as heart failure, renal failure or active gastrointestinal bleeding.

Design outcomes

Primary

Measure	Time frame
serum albumin;24-hour urinary protein;serum PLA2R antibody;	—

Countries

China

Contacts

Public ContactYaling Guo

The First Affiliated Hospital of Bengbu Medical College

guoyalingmin@163.com+86 15855783105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026